Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H25NO3 |
Molecular Weight | 291.3853 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1CCCC2=O
InChI
InChIKey=IXHBTMCLRNMKHZ-UHFFFAOYSA-N
InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3
Molecular Formula | C17H25NO3 |
Molecular Weight | 291.3853 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Bunolol is non-selective beta-adrenoreceptor antagonist with significant antihypertensive, antiarrhythmic and local anesthetic activities. Bunolol is a racemic mixture and Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity. Bunolol is 3 times as potent as propranolol by i.v. administration in anesthetized dogs in antagonizing the cardiovascular actions of isoproterenol and the response to cardioaccelerans nerve stimulation. When oral doses were given to unanesthetized dogs with subsequent induction of anesthesia, Bunolol was 20 times as potent as propranolol. The β-adrenergic blocking activity of Bunolol appeared to be competitive, and the activity was largely restricted to the l-isomer. Bunolol is extensively metabolized by both oxidative and reductive routes.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:20:11 GMT 2023
by
admin
on
Fri Dec 15 17:20:11 GMT 2023
|
Record UNII |
71QSY2UT3G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71QSY2UT3G
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
C166977
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL293030
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
58612
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
SUB05979MIG
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
3914
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
29110
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
26718-17-2
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
SUPERSEDED | |||
|
2762
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
27591-01-1
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
DTXSID7022702
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY | |||
|
100000088447
Created by
admin on Fri Dec 15 17:20:11 GMT 2023 , Edited by admin on Fri Dec 15 17:20:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |